14. Use of a dry powder formulation according to any one of claims 1 to 9 in the manufacture of a medicament for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.

15. The use according to claim 14, wherein the inflammatory and/or obstructive airways disease is chronic obstructive pulmonary disease (COPD).